1-DASA-ATPMS@CP1@Eth restored cardiomyocyte survival to 92.1%, significantly surpassing free Eth at 75.9%, in Ang II-treated H9c2 cells.
null
Does 1-DASA-ATPMS@CP1@Eth nanoparticle delivery of ethoxysanguinarine improve cell viability and reduce apoptosis in Ang II-treated H9c2 cardiomyocytes?
The engineered 1-DASA-ATPMS@CP1@Eth nanocomposite successfully delivers ethoxysanguinarine to Ang II-treated cardiomyocytes, amplifying its anti-apoptotic efficacy and offering a potential targeted theranostic strategy for hypertensive heart disease.
Effect estimate: null (95% CI null)
Absolute Event Rate: 92.1% vs 75.9%
p-value: p=<0.001
Hypertensive heart disease (HHD) arises from chronic hypertension--induced cardiac remodeling (characterized by concentric hypertrophy, fibrosis, and diastolic dysfunction) and is driven, in part, by Ang II--mediated cardiomyocyte apoptosis, oxidative stress, and fibrotic signaling. To address this, we engineered a 1-DASA-ATPMS@CP1@Eth nanocomposite, synthesized by conjugating compound 1 to DASA and grafting onto 3-Aminopropyltrimethoxysilane (ATPMS) to form ∼200 nm spheres, then encapsulating CP1 (85% loading) and adsorbing ethoxysanguinarine (Eth). In Ang II–treated H9c2 cells, Eth-loaded nanoparticles (Eth-NPs) significantly preserved cell viability (CCK-8 assay) and down-regulated pro-apoptotic Bax mRNA (qPCR) compared to free Eth or blank nanoparticles. These findings indicate that the nanoparticle delivery system amplifies Eth’s anti-apoptotic efficacy and offers a promising strategy for targeting cardiomyocyte apoptosis in HHD treatment.
Zhou et al. (Tue,) conducted a null in Hypertensive heart disease. 1-DASA-ATPMS@CP1@Eth vs. blank nanoparticles, free Eth, Eth-NPs was evaluated on cell viability and pro-apoptotic Bax mRNA expression (null, 95% CI null, p=<0.001). 1-DASA-ATPMS@CP1@Eth restored cardiomyocyte survival to 92.1%, significantly surpassing free Eth at 75.9%, in Ang II-treated H9c2 cells.